PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α

Z Qu, S Wang, R Teng, X Yi - Molecular and cellular biochemistry, 2014 - Springer
Z Qu, S Wang, R Teng, X Yi
Molecular and cellular biochemistry, 2014Springer
This study is to determine if PU-H71, a heat shock protein inhibitor, induces killing of
malignant breast cells together with treatment of tumor necrosis factor-α (TNF-α). The related
molecular mechanisms were also studied. A primary mammary epithelial cell line
HMEC2595 cells and the highly metastatic breast cell line MDA-MB-231, the HER2-positive
BT-474 cells, and the ER-positive MCF7 cells were treated with PU-H71 in the presence or
absence of TNF-α. The effects of PU-H71 and TNF-α treatments on cells viabilities and on …
Abstract
This study is to determine if PU-H71, a heat shock protein inhibitor, induces killing of malignant breast cells together with treatment of tumor necrosis factor-α (TNF-α). The related molecular mechanisms were also studied. A primary mammary epithelial cell line HMEC2595 cells and the highly metastatic breast cell line MDA-MB-231, the HER2-positive BT-474 cells, and the ER-positive MCF7 cells were treated with PU-H71 in the presence or absence of TNF-α. The effects of PU-H71 and TNF-α treatments on cells viabilities and on intracellular signaling pathway proteins were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, apoptosis assays, immunoblot assays, and luciferase assays. It was found that TNF-α enhances the toxic effects of PU-H71 on tumor cells but not normal cells. PU-H71 treatments lead to degradation of IKKβ. Moreover, PU-H71 down-regulates the NF-κB transcriptional activity induced by TNF-α treatment. The experimental results indicated PU-H71 effectively induces cell killing of malignant breast cells in the presence of TNF-α, possibly through a mechanism related to degradation of IKKβ. It is suggested that combination of PU-H71 and TNF-α treatments might be an effective therapeutic strategy of breast malignancies.
Springer